>
Switch to:

Eidos Therapeutics Cash Flow from Financing

: $67.01 Mil (TTM As of Sep. 2020)
View and export this data going back to 2018. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2020, Eidos Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Eidos Therapeutics spent $0.00 Mil on financial activities for the three months ended in Sep. 2020.


Eidos Therapeutics Cash Flow from Financing Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Eidos Therapeutics Annual Data
Dec16 Dec17 Dec18 Dec19
Cash Flow from Financing 3.99 13.31 185.10 65.89

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.55 41.92 24.29 0.55 0.25

Eidos Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Eidos Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2019 is calculated as:

Eidos Therapeutics's Cash from Financing for the quarter that ended in Sep. 2020 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2020 was 41.92 (Dec. 2019 ) + 24.286 (Mar. 2020 ) + 0.554 (Jun. 2020 ) + 0.247 (Sep. 2020 ) = $67.01 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Eidos Therapeutics  (NAS:EIDX) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Eidos Therapeutics's issuance of stock for the three months ended in Sep. 2020 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Eidos Therapeutics's repurchase of stock for the three months ended in Sep. 2020 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Eidos Therapeutics's net issuance of debt for the three months ended in Sep. 2020 was $0.00 Mil. Eidos Therapeutics received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Eidos Therapeutics's net issuance of preferred for the three months ended in Sep. 2020 was $0.00 Mil. Eidos Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Eidos Therapeutics's cash flow for dividends for the three months ended in Sep. 2020 was $0.00 Mil. Eidos Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Eidos Therapeutics's other financing for the three months ended in Sep. 2020 was $0.00 Mil. Eidos Therapeutics received $0.00 Mil on other financial activities.


Eidos Therapeutics Cash Flow from Financing Related Terms


Eidos Therapeutics Cash Flow from Financing Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)